MedPath

Pentobarbital

Generic Name
Pentobarbital
Brand Names
Nembutal
Drug Type
Small Molecule
Chemical Formula
C11H18N2O3
CAS Number
76-74-4
Unique Ingredient Identifier
I4744080IR
Background

A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)

Indication

For the short-term treatment of insomnia.

Associated Conditions
Convulsions, Insomnia
Associated Therapies
Anesthetic premedication therapy, Emergency Care

A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)

Phase 1
Completed
Conditions
Heart Disease
Interventions
Other: Nasal Placebo
Other: Oral Placebo
First Posted Date
2014-09-26
Last Posted Date
2020-01-21
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
280
Registration Number
NCT02250820
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation

Not Applicable
Withdrawn
Conditions
Sedation
Interventions
First Posted Date
2009-04-08
Last Posted Date
2018-06-28
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT00878345
Locations
🇺🇸

St. Louis Children's Hospital, Saint Louis, Missouri, United States

Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension

Phase 3
Terminated
Conditions
Traumatic Brain Injury
Interventions
First Posted Date
2008-02-25
Last Posted Date
2008-02-25
Lead Sponsor
Hospital Universitari Son Dureta
Target Recruit Count
44
Registration Number
NCT00622570
Locations
🇪🇸

Son Dureta Hospital, Palma, Balearic Island, Spain

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

Phase 1
Withdrawn
Conditions
Substance-Related Disorders
Interventions
First Posted Date
2005-07-25
Last Posted Date
2016-05-12
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT00123578
Locations
🇺🇸

UCLA, Los Angeles, California, United States

Physiological, Behavioral and Subjective Effects of Drugs (GHB)

Phase 1
Completed
Conditions
Sedative Abuse
Interventions
First Posted Date
2003-04-16
Last Posted Date
2008-09-10
Lead Sponsor
Orphan Medical
Target Recruit Count
20
Registration Number
NCT00058955
Locations
🇺🇸

Johns Hopkins University School of Medicine/Bayview Medical Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath